Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
50.84
+1.53 (+3.10%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Crispr Therapeutics Ag
< Previous
1
2
Next >
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
July 11, 2024
Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.
Via
MarketBeat
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
March 20, 2024
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel
Via
MarketBeat
Exposures
Product Safety
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
Via
MarketBeat
MarketBeat Week in Review – 2/26 - 3/1
March 02, 2024
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
bluebird bio: How to play LEAPS options for growth and income
February 27, 2024
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT
Via
MarketBeat
Exposures
Product Safety
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Exposures
Product Safety
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
These 5 growth stocks are now in buy ranges
January 25, 2024
Affirm, MongoDB, UIPath, Synopsys and Crispr's charts signal buy opportunities as these top-performing tech and biotech stocks consolidate below prior highs.
Via
MarketBeat
Topics
ETFs
2 gene editing stocks to keep on your 2024 watchlist
January 23, 2024
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)
Via
MarketBeat
Exposures
Product Safety
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal
Via
MarketBeat
CRISPR Therapeutics sets sights on gene-editing cures for disease
December 27, 2023
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for
Via
MarketBeat
Exposures
Product Safety
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
December 08, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
November 16, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Why you can make Vertex Pharmaceuticals a buy on any pullback
November 08, 2023
Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely
Via
MarketBeat
Exposures
COVID-19
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
3 Biotech Stocks to Buy for Long-Term Gains
July 13, 2023
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
June 09, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
June 08, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
May 18, 2023
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.
Via
MarketBeat
Exposures
Product Safety
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
April 03, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
March 27, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
December 10, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Shares Higher On Optimism About CRISPR Partnership
October 05, 2022
Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments.
Via
MarketBeat
Exposures
Product Safety
No One Told These 3 Stocks It’s a Down Week
September 16, 2022
At the individual stock level, there have been some interesting contrarian movers, especially in the electric vehicle (EV) space.
Via
MarketBeat
Topics
Economy
Electric Vehicles
Exposures
Electric Vehicles
Interest Rates
MarketBeat: Week in Review 8/1 - 8/5
August 06, 2022
The hot jobs report is dispelling any notion that interest rates will level off. But the market moves on and here are some of the stocks and stories to follow.
Via
MarketBeat
Topics
Economy
Electric Vehicles
Exposures
Electric Vehicles
Interest Rates
Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
July 29, 2022
This article reviews the current state of affairs for CRISPR Therapeutics so you can decide if the gene editing company is worth a speculative investment
Via
MarketBeat
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
June 11, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.